ACADIA Pharmaceuticals Inc. ACAD
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 14.82% | 11.75% | 9.93% | 11.87% | 12.69% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.82% | 11.75% | 9.93% | 11.87% | 12.69% |
| Cost of Revenue | 1.06% | 6.57% | 4.91% | 8.49% | 23.67% |
| Gross Profit | 24.39% | 15.18% | 13.32% | 14.14% | 6.14% |
| SG&A Expenses | 23.45% | 18.55% | 17.11% | 12.38% | 11.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.36% | 13.32% | 11.72% | 10.67% | 16.61% |
| Operating Income | 29.57% | -4.35% | -8.44% | 24.36% | -15.88% |
| Income Before Tax | -42.55% | -54.69% | -56.54% | -46.18% | 100.21% |
| Income Tax Expenses | -1,740.66% | -666.73% | -824.36% | -897.17% | 52.63% |
| Earnings from Continuing Operations | 38.69% | 71.27% | 64.12% | 72.66% | 103.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 38.69% | 71.27% | 64.12% | 72.66% | 103.24% |
| EBIT | 29.57% | -4.35% | -8.44% | 24.36% | -15.88% |
| EBITDA | 24.52% | -5.36% | -8.81% | 16.38% | -12.91% |
| EPS Basic | 36.50% | 68.43% | 61.40% | 69.76% | 100.76% |
| Normalized Basic EPS | 20.86% | -1.87% | -4.22% | 22.59% | -4.78% |
| EPS Diluted | 36.28% | 67.47% | 60.89% | 68.71% | 100.61% |
| Normalized Diluted EPS | 20.09% | -2.52% | -4.78% | 22.09% | -4.85% |
| Average Basic Shares Outstanding | 2.09% | 1.97% | 1.75% | 1.50% | 1.34% |
| Average Diluted Shares Outstanding | 2.77% | 2.74% | 2.50% | 1.91% | 1.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |